The Chicago Entrepreneur

Eli Lilly’s new diabetes drug continues to show promise as an obesity treatment

Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.

Previous post Cramer greenlights beaten-down tech stocks, says Target’s inventory woes suggest inflation is peaking
Next post OECD cuts global growth outlook to 3%